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Background: The assessment of the benefit-risk of medicines needs careful consideration concerning their patterns
of utilization. Systems for the monitoring of medicines consumption have been established in many European
countries, and several international groups have identified and described them. No other compilation of European
working groups has been published.
As part of the PROTECT project, as a first step in searching for European data sources on the consumption of five
selected groups of medicines, we aimed to identify and describe the main characteristics of the existing
collaborative European working groups.
Findings: Google and bibliographic searches (PubMed) of articles containing information on databases and other
sources of drug consumption data were conducted. For each working group the main characteristics were recorded.
Nineteen selected groups were identified, focusing on: a) general drug utilisation (DU) research (EuroDURG, CNC, ISPE’S
SIG-DUR, EURO-MED-STAT, PIPERSKA Group, NorPEN, ENCePP, DURQUIM), b) specific DU research: b.1)
antimicrobial drugs (ARPAC, ESAC, ARPEC, ESGAP, HAPPY AUDIT), b.2) cardiovascular disease (ARITMO, EUROASPIRE),
b.3) paediatrics (TEDDY), and b.4) mental health/central nervous system effects (ESEMeD, DRUID, TUPP/EUPoMMe).
Information on their aims, methods and activities is presented.
Conclusions: We assembled and updated information on European working groups in DU research and in the
utilisation of five selected groups of drugs for the PROTECT project. This information should be useful for academic
researchers, regulatory and health authorities, and pharmaceutical companies conducting and interpreting
post-authorisation and safety studies. European health authorities should encourage national research and
collaborations in this important field for public health.
Keywords: Pharmacoepidemiology, Pharmacovigilance, European network, Drug utilisation, Drug consumption,
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unless otherwise stated.To identify and describe the main characteristics of
the existing collaborative European working groups,
we conducted a Google and bibliographic searches
(PubMed) of articles containing information on data-
bases and other sources of drug consumption data of
medicines.
Nineteen selected groups were identified, focusing on:
a) general drug utilisation (DU) research (EuroDURG,
CNC, ISPE’S SIG-DUR, EURO-MED-STAT, PIPERSKA
Group, NorPEN, ENCePP, DURQUIM), b) specific DU re-
search: b.1) antimicrobial drugs (ARPAC, ESAC, ARPEC,
ESGAP, HAPPY AUDIT), b.2) cardiovascular diseaseLtd. This is an Open Access article distributed under the terms of the Creative
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b.4) mental health/central nervous system effects (ESEMeD,
DRUID, TUPP/EUPoMMe). Information on their aims,
methods and activities is presented.
Introduction
Drug utilisation research is defined by the World Health
Organization (WHO) as “the development, regulation,
marketing, distribution, prescription, dispensing and use
of medicines within a society, with special emphasis on
the medical, social and economic consequences” [1]. A
broad definition should also include the qualitative stud-
ies for assessing the appropriateness of drug utilisation
and the intervention studies [2]. Drug utilisation re-
search plays a key role in understanding the use of medi-
cines and evaluating the effect of interventions (such as
policy changes, reimbursement policy and regulatory de-
cisions) on drug use, thereby ameliorating the quality of
care and improving public health.
The Pharmacoepidemiological Research on Outcomes
of Therapeutics by a European ConsorTium (PROTECT)
study is a collaborative European project which aims to
enhance the monitoring of the safety of medicinal prod-
ucts [3]. One of the specific objectives of PROTECT is to
build and update an inventory of data sources on the con-
sumption of medicines in the European Union as a tool to
estimate the public health impact of several adverse drug
events.
Efforts to collect information about the use of medi-
cines in European countries date from the seventies.
There is a wide international variability in drug utilisa-
tion documented in a WHO-Regional Office for Europe
sponsored meeting [4]. In addition, information about
the overall use of medicines across European countries
is of interest to estimate the public health impact of ad-
verse effects associated with the use of medicines [5,6]. As
a first step in searching for European data sources for
medicines consumption, we aimed to describe and update
the main characteristics of the collaborative international
European working groups, networks, and research pro-
jects related to drug utilisation.
Methods
Search strategy:
1. Internet search. The goal was to find institutions,
networks and research projects related to drug
utilisation in Europe in general and those focused on
six groups of drugs, namely: 1) inhaled beta-2 agonists;
2) antibiotics; 3) antidepressants 4) benzodiazepines;
5) anticonvulsants, and 6) calcium channel blockers [3].
2. Bibliographic search: (1990-2010) in PubMed and
SIETES (Sistema de Información Esencial en
Terapéutica y Salud (http://www.sietes.org), anelectronic drug information system in Spanish).
Keywords: “databases”, “drug utilization”, “drug
utilization research”, “Europe”, “international
cooperation”, “international group”, “national
databases”, “network”, “pharmacoepidemiology” and
“working group”.
Group selection criteria
Working groups were included if they were European
groups, focused on drug utilisation and/or if they were
involved in research on the medicines of interest for the
PROTECT project. This selection was done according to
pre-defined criteria such as regulatory and public health
impact, and the potential to investigate a broad range of
methodological issues [7].
Groups studying a single condition and/or those fo-
cusing only on drugs of no interest for the PROTECT
project, or based on a single European country, or not
active at the time of search, were excluded.
Data abstraction
The characteristics of each working group were collected
from their websites or from methods and acknowledge-
ment sections in published papers.
These data were analysed in a descriptive manner.
Results
Twenty-four European working groups on drug utilisation
were identified, nineteen of which fulfilled our eligibility
criteria. Additional information on excluded groups can
be found on (http://www.icf.uab.es/EuropeanWG).
The characteristics of the working groups are described
in the Additional file 1: Table S1. Eight groups focused on
promoting general drug utilisation research and eleven fo-
cused on specific fields.
Discussion
As far as we know, no other compilation of European
collaborative working groups and their sources of data
on medicines utilisation have been published.
Nineteen European groups were selected: eight groups
were interested in general drug utilisation research or
pharmacoepidemiology, with the common objective of com-
piling information on data sources, either at a European
level (e.g., ENCePP in Europe) or at a more restricted geo-
graphical level (e.g., NorPen in the Nordic countries). The
remaining eleven groups focused their research on specific
fields, mainly antimicrobials, cardiovascular conditions,
paediatrics, and mental health (e.g., ESAC: antimicrobials,
EUROASPIRE: cardiovascular conditions).
Among the groups focusing on general drug utilisa-
tion the EURO-MED-STAT widened the initial Euro-
Medicines project and developed a European database
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countries [8].
The CNC project offered a wide range of sources of
medicines consumption data for eighteen countries.
However, the information is not published but available
on a website [9], and it is not clear whether the informa-
tion has been kept updated.
EnCePP, led by the European Medicines Agency (EMA),
was established to strengthen the postmarketing monitor-
ing of medicines. Its website contains a voluntary register
of the healthcare databases existing in all European coun-
tries including those monitoring drug consumption.
Our search identified several European working groups
collecting information on the utilisation of the selected
groups of medicine even though their main objective goes
beyond the collection of drug consumption data.
As expected, we found wide heterogeneity in the na-
ture and quality of the drug utilisation data among the
groups. The main factors determining their heterogen-
eity were: a) variability in the population coverage, and
in the number of countries involved in each working
group; b) differences in medicines coding systems, and
c) source of the drug utilisation data (e.g., questionnaires
to individuals, samples or registers of prescribed/dispensed
medicines). In addition, none of the groups, except ESAC,
has tried to validate drug utilisation data [10].
Inhaled beta-2 agonists and anticonvulsants did not
appear in our search in relation to medicines consumption.
This could be explained by the fact that the groups work-
ing in those areas concentrate more on risk factors associ-
ated with diseases rather than on exposure to medicines.
Most of the initiatives in this field have received public
funding. As a consequence a lot of good initiatives and
efforts could have been lost if this funding had ended.
Funding is decisive in keeping these research working
groups ongoing.
The general working groups contribute to the collab-
oration in pharmacoepidemiology and specifically in
drug utilisation research studies across the European
countries through improving the research in this field
and the quality of health care management. For example,
PIPERSKA contributes to enhancing the rational use
of drugs in different countries and the Nordic net-
work NorPEN facilitates and promotes safer and more
efficient medicines in a public health perspective in
the Nordic countries. Among its goals there is the object-
ive to increase quality of research and methodological
development within pharmacoepidemiology in the Nordic
countries.
The importance and impact of the specific drug util-
isation groups in the medical community stems from the
collaborative research in drug utilisation and methodo-
logical innovation as well as from aspects derived from
their field of interest. For instance, the groups focusingon antibiotics such as ESAC, have contributed not only
to a specific field such as the use of antibiotics in Europe
but to guidelines for methods in drug utilisation research
(i.e, study design and comparison of drug utilisation data
across different countries). The field of antimicrobial
drugs has traditionally interested European researchers
due to its relationship with the appearance of resistances.
Those groups interested in cardiovascular diseases such as
ARITMO or EUROASPIRE work on diseases with a high
public health impact [11], and they have been active for a
long time. Their importance also lies in their interest in
adverse drug reactions and in prognostic factors for dis-
ease prevention. Other initiatives such as TEDDY focus
on the paediatric population. TEDDY has the purpose of
promoting the availability of safe and effective paediatric
drugs to overcome the difficulties and complexity of
research in this population. It continues the activities
through the participation in other on-going projects
(ex Global Research in Paediatrics (GRIP)). Finally the
research groups focusing on mental diseases derive
their importance from the high prevalence of mental
diseases worldwide [12].
The strengths of our compilation are the standardised
search and the categorising of the information as general
and specific-related drug utilisation areas in Europe. The
broad search lets us find out about the general groups
on drug utilisation as well as those focusing on the se-
lected PROTECT drugs. This paper highlights some of
the benefits of international collaboration such as the
possibility of sharing and transferring knowledge and the
high number of participating countries involved. This
international collaboration is also important for pharma-
covigilance activities, to enable the regulatory institutions
such as the EMA to obtain fast and reliable information
for population benefit-risk assessment. It also facilitates
regulatory decision-making and assessing the public health
impact of the use of medicines [13]. In addition, this com-
pilation can promote networking between researchers and
contribute to multidatabase studies which are of increasing
interest for drug safety issues nowadays (ie, ESAC, TEDDY,
GRIP).This work has provided not only an overview of the
availability of drug utilisation data for the drug-adverse
event pairs included in the PROTECT project, but also
an update on the methodological framework for drug
utilisation studies [10,14,15]. Finally, the access to the in-
formation and knowledge held by the groups are described.
Researchers can use this information in pharmacoepidemio-
logical studies to improve patient’s therapeutic management.
Our research has some limitations. First, some working
groups could have been missed because of the difficulty in
understanding some non-English language websites. Second,
although we conducted a complete search, part of the re-
sults refers only to the drugs of interest for the PROTECT
project. Third, the information about the data on medicines
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tracted from their website or from the methods section in
the published references, which is sometimes summarised.
Finally, the update of the information has been difficult
because the websites are not updated regularly.
Conclusion
We assembled and updated information on European
working groups in drug utilisation research and in the util-
isation of five selected groups of drugs for the PROTECT
project. A description of the main working groups and
information on their data characteristics has been pro-
vided. This information should be of value for academic
researchers, regulatory authorities, health authorities and
pharmaceutical companies conducting and interpreting
post-authorisation and safety studies. European and mem-
ber states’ health authorities should encourage and sup-
port national research and European collaboration in this
important field for public health.Additional file
Additional file 1: Table S1. European working groups on general drug
utilisation and on specific fields on drug utilisation.Abbreviations
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